BX005

AXP000219.1 · Phage therapy

Platform
phage cocktail (non-engineered)
Originator
BiomX
Sponsor
BiomX

Names

NameTypeSource
BX005preferred name, codecurator, ctgov
BX005-Acodectgov

Virus

Role
Phage
Family
Caudoviricetes
Virus
Staphylococcus aureus bacteriophage (cocktail)
Replication
replicating
Route
topical
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT05240300A Study of Topical BX005-A in Subjects With Moderate to Severe Atopic DermatitisWithdrawnPhase 1/22022-052023-060Atopic Dermatitis

Recent changes

No changes recorded in its trials yet.

Clinical papers

No confirmed clinical papers yet.

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 38212021[Comprehensive evaluation of Pinellia ternata germplasm resources based on phenotypic trait classification].Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica2023name in abstract: BX005

Notes

Topical anti-Staphylococcus aureus phage cocktail for atopic dermatitis. Its registered phase 1b/2a trial NCT05240300 was withdrawn, so the product has a registered trial but no published human use; kept on the registered-trial limb of the scope rule and flagged here.

How to cite

BX005 (AXP000219.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000219.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.